Top Markets
Coin of the day
Caliway Biopharmaceuticals Co. L Caliway Biopharmaceuticals Co. L

Caliway Biopharmaceuticals Co. L

6919
Rank in Stocks #3556
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Share Price
$3.28
Last synced: 2026-07-31
Market Cap
$5.10B
Change (1 day)
0.00%
Change (1 year)
-49.70%
Country
TW
Trade Caliway Biopharmaceuticals Co. L (6919)

Category

P/B ratio for Caliway Biopharmaceuticals Co. L (6919)
P/B ratio as of 2026 TTM: 0
According to Caliway Biopharmaceuticals Co. L latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Caliway Biopharmaceuticals Co. L from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH